001     132485
005     20240229105018.0
024 7 _ |a 10.1093/neuonc/nox141
|2 doi
024 7 _ |a pmid:29016845
|2 pmid
024 7 _ |a pmc:PMC5786244
|2 pmc
024 7 _ |a 1522-8517
|2 ISSN
024 7 _ |a 1523-5866
|2 ISSN
024 7 _ |a altmetric:32070368
|2 altmetric
037 _ _ |a DKFZ-2018-00172
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Jones, David
|0 P:(DE-He78)551bb92841f634070997aa168d818492
|b 0
|e First author
|u dkfz
245 _ _ |a Pediatric low-grade gliomas: next biologically driven steps.
260 _ _ |a Oxford
|c 2018
|b Oxford Univ. Press
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1659955578_8497
|2 PUB:(DE-HGF)
|x Review Article
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Despite the fact that they are not typically life-threatening, low-grade gliomas (LGGs) remain a significant clinical challenge in pediatric neuro-oncology due to comorbidities associated with these tumors and/or their treatments, and their propensity to multiply recurs. LGGs, in total the most common brain tumors arising in childhood, can often become a chronic problem requiring decades of management. The Second International Consensus Conference on Pediatric Low-Grade Gliomas held in Padua, Italy in 2016 was convened in an attempt to advance the pace of translating biological discoveries on LGGs into meaningful clinical benefit. Topics discussed included: the implications of our growing biological understanding of the genomics underlying these tumors; the assessment of the model systems available; the implications of the molecular and histopathologic differences between adult and pediatric diffuse gliomas; and steps needed to expedite targeted therapy into late-stage clinical trials for newly diagnosed cases. Methods for the diagnostic assessment of alterations in the Ras/mitogen-activated protein kinase pathway, typical for these tumors, were also considered. While the overall tone was positive, with a consensus that progress is being and will continue to be made, the scale of the challenge presented by this complex group of tumors was also acknowledged. The conclusions and recommendations of the meeting panel are provided here as an outline of current thinking and a basis for further discussion.
536 _ _ |a 312 - Functional and structural genomics (POF3-312)
|0 G:(DE-HGF)POF3-312
|c POF3-312
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Kieran, Mark W
|b 1
700 1 _ |a Bouffet, Eric
|b 2
700 1 _ |a Alexandrescu, Sanda
|b 3
700 1 _ |a Bandopadhayay, Pratiti
|b 4
700 1 _ |a Bornhorst, Miriam
|b 5
700 1 _ |a Ellison, David
|b 6
700 1 _ |a Fangusaro, Jason
|b 7
700 1 _ |a Fisher, Michael J
|b 8
700 1 _ |a Foreman, Nicholas
|b 9
700 1 _ |a Fouladi, Maryam
|b 10
700 1 _ |a Hargrave, Darren
|b 11
700 1 _ |a Hawkins, Cynthia
|b 12
700 1 _ |a Jabado, Nada
|b 13
700 1 _ |a Massimino, Maura
|b 14
700 1 _ |a Mueller, Sabine
|b 15
700 1 _ |a Perilongo, Giorgio
|b 16
700 1 _ |a Schouten van Meeteren, Antoinette Y N
|b 17
700 1 _ |a Tabori, Uri
|b 18
700 1 _ |a Warren, Katherine
|b 19
700 1 _ |a Waanders, Angela J
|b 20
700 1 _ |a Walker, David
|b 21
700 1 _ |a Weiss, William
|b 22
700 1 _ |a Witt, Olaf
|0 P:(DE-He78)143af26de9d57bf624771616318aaf7c
|b 23
|u dkfz
700 1 _ |a Wright, Karen
|b 24
700 1 _ |a Zhu, Yuan
|b 25
700 1 _ |a Bowers, Daniel C
|b 26
700 1 _ |a Pfister, Stefan
|0 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9
|b 27
|u dkfz
700 1 _ |a Packer, Roger J
|b 28
773 _ _ |a 10.1093/neuonc/nox141
|g Vol. 20, no. 2, p. 160 - 173
|0 PERI:(DE-600)2094060-9
|n 2
|p 160 - 173
|t Neuro-Oncology
|v 20
|y 2018
|x 1523-5866
909 C O |p VDB
|o oai:inrepo02.dkfz.de:132485
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)551bb92841f634070997aa168d818492
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 23
|6 P:(DE-He78)143af26de9d57bf624771616318aaf7c
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 27
|6 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-312
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Functional and structural genomics
|x 0
914 1 _ |y 2018
915 _ _ |a Allianz-Lizenz / DFG
|0 StatID:(DE-HGF)0400
|2 StatID
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NEURO-ONCOLOGY : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b NEURO-ONCOLOGY : 2015
920 1 _ |0 I:(DE-He78)B062-20160331
|k B062
|l B062 Pädiatrische Neuroonkologie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)B062-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21